Mircera - 2007 FDA approvals

Drug: Mircera
Indication: Anemia
Company: Roche
Approval Date: November 14, 2007

Scoop: Mircera has a longer half-life than other commercially available erythropoiesis-stimulating agents (ESA). However, Roche lost a patent infringement case to Amgen, which markets the bestselling--and controversial--anti-anemia drugs Aranesp and Epogen. Though Mircera is available overseas, for the forseeable future it will not be marketed in the U.S.

More news:
Mircera gets FDA nod, but blocked by patent case. Report
Roche: Patent ruling won't stop Mircera. Report
Roche to Launch Mircera in UK and Germany. Report

Mircera - 2007 FDA approvals
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.